The company said it held its annual meeting of shareholders virtually on May 4, 2026. As of the record date, February 27, 2026, there were 72,081,610 shares of common stock outstanding, and 66,193,322 shares (91.83%) were represented at the meeting, it reported.

1. 01

   The company said it held its annual meeting of shareholders virtually on May 4, 2026. As of the record date, February 27, 2026, there were 72,081,610 shares of common stock outstanding, and 66,193,322 shares (91.83%) were represented at the meeting, it reported.

2. 02

   West Pharmaceutical Services said all 11 director nominees were elected, each to serve until the 2027 annual meeting of shareholders. Stephen H. Lockhart received 63,432,380 votes for and 470,840 against, while Deborah L. V. Keller received 57,992,162 votes for and 5,599,392 against.

3. 03

   The company said the non-binding advisory vote on executive compensation was approved, with 60,107,802 votes for and 3,762,206 against. It also reported that the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 was approved, with 58,509,119 votes for and 7,556,514 against.

4. 04

   West Pharmaceutical Services said a shareholder proposal on an Independent Board Chair Policy was not approved. The vote was 29,592,488 for and 34,245,125 against.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.